Merck beats Q2 revenue estimates with US$16.61 billion as Keytruda sales rise 5%

Merck reported second-quarter revenue of US$16.61 billion, up 5% year on year and above the US$16.36 billion analysts expected, with Keytruda sales rising 5% to US$8.37 billion. The company posted a quarterly loss of 13 cents per share after a US$2.31 per share charge tied to its acquisition of Terns Pharmaceuticals. Animal health revenue rose 8% to US$1.78 billion, slightly ahead of expectations.